Corpus overview


MeSH Disease

Human Phenotype

Pneumonia (36)

Fever (18)

Cough (9)

Falls (8)

Anxiety (6)


    displaying 1 - 10 records in total 340
    records per page

    Quantification of a Viromed Klinik Akut V 500 disinfection device to reduce the indirect risk of SARS-CoV-2 infection MESHD by aerosol particles

    Authors: Christian J. Kähler; Thomas Fuchs; Rainer Hain; Nathanaël Beeker; Antoine Neuraz; Jesús Alvarado; Christel Daniel; Nicolas Paris; Alexandre Gramfort; Guillaume Lemaitre; Elisa Salamanca; Mélodie Bernaux; Ali Bellamine; Anita Burgun; Frédéric Limosin; Carl Kendall

    doi:10.1101/2020.10.23.20218099 Date: 2020-10-27 Source: medRxiv

    Indoor SARS-CoV-2 infections MESHD by droplets and aerosols are currently considered to be particularly significant. FFP2/3 respirator masks, which fit tightly and gap free, generally provide very good protection. In public transport, while shopping or in waiting rooms, they are therefore ideally suited to protect against direct and indirect infection MESHD. Unfortunately, these masks make it difficult to breathe and can be uncomfortable to wear in the long run. Therefore, these masks should be worn for a maximum of 3 x 75 minutes per day. These masks are therefore hardly suitable for schools or at work. The question therefore arises as to how people in closed rooms can be permanently protected from a SARS-CoV-2 infection MESHD. Large safety distances provide both self protection and protection of third parties, but they do not protect against indirect infection if the virus load in the room is high. Mouth and nose covers only offer protection of others against direct infection, but they do not protect the user against indirect infection MESHD. The same applies to faceshields and small protective walls. Indirect infections can be effectively prevented by free ventilation with windows or air conditioning systems that supply 100% outside air into the room, provided the air exchange rate is at minimum six times the room volume per hour. However, free ventilation by means of windows is rarely efficient enough, and in winter at the latest, it is no longer possible to open windows without wasting massive amounts of energy and endangering the health and well-being of people. The operation of air conditioning systems is also very energy-intensive during the cold season. Furthermore, most buildings do not have air conditioning systems. The question is therefore, how a largely safe protection against an indirect SARS-CoV-2 infection MESHD can be realized in closed rooms without wasting thermal energy and thus valuable resources. Technically, the problem can be solved with mobile disinfection devices or room air cleaners that separate the dangerous aerosol particles or inactivate the viruses by UV radiation or by contact with charge carriers TRANS. The potential of these devices is great and, since many German manufacturers produce these devices, they are also available. However, many of the devices offered do not provide effective protection because the volume flow is too small, the separation efficiency of the filters is too low and the performance SERO of the UV and ionization unit is too weak. The Viromed Klinik Akut V 500 disinfection unit appears to meet the performance SERO requirements and therefore the device is analyzed and evaluated in this study for its suitability to protect against SARS-CoV-2 infection MESHD.

    Seroprevalence SERO of SARS-CoV-2 antibodies SERO and associated factors in health care workers: a systematic review and meta-analysis

    Authors: Petros A Galanis; Irene Vraka; Despoina Fragkou; Angeliki Bilali; Daphne Kaitelidou; tanzeela Qazi; iqra chowdry; muhammad Obaid; Iram Sabah; Misbah Kawoosa; Abdul Lone; Shahroz Nabi; Ishtiyaq Sumji; Nikoloz Chkhartishvili; Frédéric Limosin; Carl Kendall

    doi:10.1101/2020.10.23.20218289 Date: 2020-10-27 Source: medRxiv

    Background: Health care workers (HCWs) represent a high risk population for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. Aim: To determine the seroprevalence SERO of SARS-CoV-2 antibodies SERO among HCWs, and to find out the factors that are associated with this seroprevalence SERO. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were applied for this systematic review and meta-analysis. Databases including PubMed/MEDLINE and pre-print services (medR{chi}iv and bioR{chi}iv) were searched from inception up to August 24, 2020. Findings: Fifty studies, including 184,898 HCWs met the inclusion criteria. The estimated overall seroprevalence SERO of SARS-CoV-2 antibodies SERO among HCWs was 8.4% (95% CI: 6.1-11.1%). Seroprevalence SERO was higher in studies that were conducted in North America (12.7%) compared to those in Africa (8.2), Europe (8.1%) and Asia (4%). Meta-regression showed that increased sensitivity SERO of antibodies test SERO was associated with increased seroprevalence SERO. The following factors were associated with seropositivity: male TRANS gender TRANS, Black, Asian, and Hispanic HCWs, work in a coronavirus disease MESHD 2019 (COVID-19) unit, patient-related work, frontline health care workers, health care assistants, personal protective equipment shortage, self-reported belief for previous SARS-CoV-2 infection MESHD, previous positive polymerase chain reaction test, and household contact TRANS with suspected or confirmed COVID-19 patients. Conclusion: The seroprevalence SERO of SARS-CoV-2 antibodies SERO among HCWs is high. Excellent adherence to infection MESHD prevention and control measures, sufficient and adequate personal protective equipment, and early recognition, identification and isolation of HCWs that are infected with SARS-CoV-2 are imperative to decrease the risk of SARS-CoV-2 infection MESHD.

    Seroprevalence SERO of anti-SARS-CoV-2 IgG Antibodies SERO in the Staff of a Public School System in the Midwestern United States

    Authors: Lilah Lopez; Graham Weber; Thao Nguyen; Katlyn Kleimola; Megan Bereda; Yiling Liu; Emma K. Accorsi; Steven J. Skates; John P. Santa Maria; Kendal R. Smith; Mark Kalinich; Walter Krugluger; Christian Sebesta; Harald Herkner; Brenda Laky; Ali Bellamine; Anita Burgun; Frédéric Limosin

    doi:10.1101/2020.10.23.20218651 Date: 2020-10-27 Source: medRxiv

    Background Since March 2020, the United States has lost over 200,000 lives to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), which causes COVID-19. A growing body of literature describes population-level SARS-CoV-2 exposure, but studies of antibody SERO seroprevalence SERO within school systems are critically lacking, hampering evidence-based discussions on school reopenings. The Lake Central School Corporation (LCSC), a public school system in suburban Indiana, USA, assessed SARS-CoV-2 seroprevalence SERO in its staff and identified correlations between seropositivity and subjective histories and demographics. Methods This study is a cross-sectional, population-based analysis of the seroprevalence SERO of SARS-CoV-2 in LCSC staff measured in July 2020. We tested for seroprevalence SERO with the Abbott Alinity SARS-CoV-2 MESHD IgG antibody SERO test. The primary outcome was the total seroprevalence SERO of SARS-CoV-2, and secondary outcomes included trends of antibody SERO presence in relation to baseline attributes. Findings 753 participants representative of the staff at large were enrolled. 22 participants (2.9%, 95% CI: 1.8% - 4.4%) tested positive for SARS-CoV-2 antibodies SERO. Correcting for test performance SERO parameters, the seroprevalence SERO is estimated at 1.7% (90% Credible Interval: 0.27% - 3.3%). Multivariable logistic regression including mask wearing, travel TRANS history, symptom history, and contact history revealed a 48-fold increase in the odds of seropositivity if an individual previously tested positive for COVID-19 (OR: 48.2, 95% CI: 4 - 600). Amongst individuals with no previous positive test, exposure to a person diagnosed with COVID-19 increased the odds of seropositivity by 7-fold (OR: 6.5, 95% CI: 2.06 - 18.9). Interpretation Assuming the presence of antibodies SERO is associated with immunity against SARS-CoV-2 infection MESHD, these results demonstrate a broad lack of herd immunity amongst the school corporation staff irrespective of employment role or location. Protective measures like contact tracing TRANS face coverings, and social distancing are therefore vital to maintaining the safety of both students and staff as the school year progresses.

    Serologic SARS-CoV-2 testing in healthcare workers with positive RT-PCR test or Covid-19 related symptoms

    Authors: Giovanni Visci; Vittorio Lodi; Roberta Bonfiglioli; Tiziana Lazzarotto; Francesco Saverio Violante; Paolo Boffetta; Young-Ki Lee; Lance Reed; Michael Rogers; Alicia Prichard; Scott Paul; George Scholl; Nicholas James Loman; Aine O'Toole; Samuel M. Nicholls; Kris V. Parag; Emily Scher; Tetyana I. Vasylyeva; Erik M. Volz; Alexander Watts; Isaac I. Bogoch; Kamran Khan; - COG-UK consortium; David Aanensen; Moritz U.G. Kraemer; Andrew Rambaut; Oliver Pybus

    doi:10.1101/2020.10.25.20219113 Date: 2020-10-27 Source: medRxiv

    Background. Limited information is available on prevalence SERO and determinants of serologic response to SARS-CoV-2 infection MESHD among healthcare workers (HCWs). Methods. We analyzed the results of serologic testing SERO with chemiluminescence immunoassay SERO analyzer (CLIA), lateral flow immunoassay SERO (LFIA) and enzyme-linked immunosorbent assay SERO ( ELISA SERO) test among 544 HCWs with at least one positive RT-PCR test and 157 HCWs with Covid-19 related symptoms without a positive RT-PCR test from public hospitals in Bologna, Northern Italy. Tests were performed between March and August 2020. We fitted multivariate logistic regression models to identify determinants of positive serology. Results. The sensitivity SERO of SARS-CoV-2 was 75.2% (LFIA) and 90.6% (CLIA). No differences in seropositivity were observed by sex, while older HCWs had higher positivity than other groups, and nurses had higher positivity compared to physicians, but not other HCWs. An estimated 73.4% of HCWs with Covid-19 symptoms without RT-PCR test were not infected with SARS-CoV-2. Conclusions. Our study provides the best available data on sensitivity SERO of serologic tests SERO and on determinants of serologic response among HCWs positive for SARS-CoV-2, and provide evidence on the low specificity of Covid-19 related symptoms to identify infected HCWs MESHD.

    Patterns of Multimorbidity and Risk of Severe SARS-CoV-2 Infection MESHD: an observational study in the U.K.

    Authors: Yogini V Chudasama; Francesco Zaccardi; Clare L Gillies; Cameron Razieh; Thomas Yates; David E Kloecker; Alex V Rowlands; Melanie J Davies; Nazrul Islam; Samuel Seidu; Nita G Forouhi; Kamlesh Khunti; Deverick J. Anderson; Jimmie Mancell; David Ho; Nathan D. Grubaugh; Yonatan H. Grad; Riina Janno; Irja Lutsar; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20216721 Date: 2020-10-23 Source: medRxiv

    Background Pre-existing comorbidities have been linked to SARS-CoV-2 infection MESHD but evidence is sparse on the importance and pattern of multimorbidity (2 or more conditions) and severity of infection MESHD indicated by hospitalisation or mortality. We aimed to use a multimorbidity index developed specifically for COVID-19 to investigate the association between multimorbidity and risk of severe SARS-CoV-2 infection MESHD. Methods We used data from the UK Biobank linked to laboratory confirmed test results for SARS-CoV-2 infection MESHD and mortality data from Public Health England between March 16 and July 26, 2020. By reviewing the current literature on COVID-19 we derived a multimorbidity index including: 1) angina MESHD; 2) asthma HP; 3) atrial fibrillation HP atrial fibrillation MESHD; 4) cancer MESHD; 5) chronic kidney disease HP kidney disease MESHD; 6) chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD; 7) diabetes mellitus HP diabetes mellitus MESHD; 8) heart failure MESHD; 9) hypertension HP hypertension MESHD; 10) myocardial infarction HP myocardial infarction MESHD; 11) peripheral vascular disease MESHD; 12) stroke HP stroke MESHD. Adjusted logistic regression models were used to assess the association between multimorbidity and risk of severe SARS-CoV-2 infection MESHD (hospitalisation or death MESHD). Potential effect modifiers of the association were assessed: age TRANS, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25-hydroxyvitamin D, cardiorespiratory fitness MESHD, high sensitivity SERO C-reactive protein. Results Among 360,283 participants, the median age TRANS was 68 [range, 48-85] years, most were White (94.5%), and 1,706 had severe SARS-CoV-2 infection MESHD. The prevalence SERO of multimorbidity was more than double in those with severe SARS-CoV-2 infection MESHD (25%) compared to those without (11%), and clusters of several multimorbidities were more common in those with severe SARS-CoV-2 infection MESHD. The most common clusters with severe SARS-CoV-2 infection MESHD were stroke HP stroke MESHD with hypertension HP hypertension MESHD (79% of those with stroke HP stroke MESHD had hypertension HP hypertension MESHD); diabetes MESHD and hypertension HP hypertension MESHD (72%); and chronic kidney disease HP chronic kidney disease MESHD and hypertension HP hypertension MESHD (68%). Multimorbidity was independently associated with a greater risk of severe SARS-CoV-2 infection MESHD (adjusted odds ratio 1.91 [95% confidence interval 1.70, 2.15] compared to no multimorbidity). The risk remained consistent across potential effect modifiers, except for greater risk among men. Conclusion The risk of severe SARS-CoV-2 infection MESHD is higher in individuals with multimorbidity, indicating the need to target research and resources in people with SARS-CoV-2 infection MESHD and multimorbidity.

    SARS-CoV-2 antibodies SERO in the Southern Region of New Zealand, 2020

    Authors: Alyson Craigie; Reuben McGregor; Alana Whitcombe; Lauren Carlton; David Harte; Michelle Sutherland; Matthew Parry; Erasmus Smit; Gary McAuliffe; James Ussher; Nicole Moreland; Susan Jack; Arlo Upton; Danielle Skinner; Ken Hirata; Sungjun Beck; Aaron F Carlin; Alex E. Clark; Laura Berreta; Daniel Maneval; Felix Frueh; Brett L Hurst; Hong Wang; Klaudia I Kocurek; Frank M Raushel; Jair L. Siqueira-Neto; Thomas D Meek; James H McKerrow

    doi:10.1101/2020.10.20.20215616 Date: 2020-10-23 Source: medRxiv

    Background: During New Zealand's first outbreak in early 2020 the Southern Region had the highest per capita SARS-CoV-2 infection MESHD rate. PCR testing was initially limited by a narrow case definition and limited laboratory capacity, so cases may have been missed. Objectives: To evaluate the Abbott SARS-CoV-2 MESHD IgG nucleocapsid assay, alongside spike-based assays, and to determine the frequency of antibodies SERO among PCR-confirmed and probable cases, contacts, and higher risk individuals in the Southern Region of NZ. Study design: Pre-pandemic sera (n=300) were used to establish assay specificity and sera from PCR-confirmed SARS-CoV-2 patients (n=78) to establish sensitivity SERO. For prevalence SERO analysis, all samples (n=1214) were tested on the Abbott assay, and all PCR- confirmed cases TRANS (n=78), probable cases (n=9), and higher risk individuals with grey-zone (n=14) or positive results (n=11) were tested on four additional SARS-CoV-2 serological assays SERO. Results: The median time from infection MESHD onset to serum SERO collection for PCR- confirmed cases TRANS was 14 weeks (range 11-17 weeks). The Abbott assay demonstrated a specificity of 99.7% (95% CI, 98.2%-99.99%) and a sensitivity SERO of 76.9% (95% CI, 66.0%-85.7%). Spike-based assays demonstrated superior sensitivity SERO ranging 89.7-94.9%. Nine previously undiagnosed sero-positive individuals were identified, and all had epidemiological risk factors. Conclusions: Spike-based assays demonstrated higher sensitivity SERO than the Abbott IgG assay, likely due to temporal differences in antibody SERO persistence. No unexpected SARS-CoV-2 infections MESHD were found in the Southern region of NZ, supporting the elimination status of the country at the time this study was conducted.

    Comparison of three nasopharyngeal swab types and the impact of physiochemical properties for optimal SARS-CoV-2 detection

    Authors: Trish R Kahamba; Lara Noble; Lesley Scott; Wendy Stevens; Zahin Amin-Chowdhury; Jessica Flood; Ray Borrow; Ezra Linley; Shazaad Ahmad; Lorraine Stapley; Bassam Hallis; Gayatri Amirthalingam; Ben Parker; Alex Horsley; Timothy J G Brooks; Kevin Brown; Mary Ramsay; Shamez Ladhani; Paula Veronica Martini Maciel; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20206078 Date: 2020-10-23 Source: medRxiv

    Adequate swab specimen collection, release and detection of nucleic acids by molecular diagnostic assays is largely attributed to the physical and chemical characteristics of different swab types. We investigated properties of three types of commercial nasopharyngeal swabs (nylon flocked: Type 1-Media Merge; Type 2- Kang Jian Medical Apparatus, China and Type 3- Wuxi NEST Biotechnology Co. Ltd, China) used in clinical diagnostics with the aim to establish if different swab designs and configurations had any effect on swab performance SERO. Properties investigated included viral absorption, release, capture, extraction and recovery efficiency from each swab for the detection of Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-CoV-2). All swab types (n=18) were inoculated with different amounts of SARS-CoV-2 live viral cultures (1:10, 1:100 and 1:1000 copies/ml) and eluted in sterile phosphate buffer saline. RNA was extracted from all swab eluates using a fully automated system (BD MAX System) and cycle threshold (Ct) values were compared. RNA stability was also investigated after dry storage of swabs at room temperature for 72 hours. Statistically significant differences (p<0.05) were observed in the absorption and release capabilities between Type 1 and 3 as well as between Type 2 and 3 swabs, however, no significant difference was observed between Type 1 and 2. Ct values and extraction efficiency amounts of SARS-CoV-2 varied amongst the swab types. We conclude that in order to facilitate accurate SARS-CoV-2 diagnosis, assessment of NP swab characteristics is of importance before implementation for specimen collection in the clinical setting.

    From multiplex serology to serolomics: A novel approach to the antibody SERO response against the SARS-CoV-2 proteome

    Authors: Julia Butt; Rajagopal Murugan; Theresa Hippchen; Sylvia Olberg; Monique van Straaten; Hedda Wardemann; Erec Stebbins; Hans-Georg Kraeusslich; Ralf Bartenschlager; Hermann Brenner; Vibor Laketa; Ben Schoettker; Barbara Mueller; Uta Merle; Tim Waterboer; James Watmough; Jude Dzevela Kong; Iain Moyles; Huaiping Zhu

    doi:10.1101/2020.10.19.20214916 Date: 2020-10-21 Source: medRxiv

    Background: The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays SERO to assess SARS-CoV-2 epidemiology. We therefore aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody SERO responses to the SARS-CoV-2 proteome. Methods: Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance SERO was assessed in a Covid-19 case cohort (n=48 hospitalized patients from Heidelberg) as well as n=85 age TRANS- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial Enzyme-linked immunosorbent ( ELISA) assays SERO. Results: A sensitivity SERO of 100% (95% CI: 86%-100%) was achieved in Covid-19 patients 14 days post symptom onset TRANS with dual sero-positivity to SARS-CoV-2 N MESHD and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96%-100%). Antibody SERO responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N MESHD. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody SERO response. Conclusion: This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity SERO and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero- prevalence SERO.

    Real-life validation of the Panbio COVID-19 Antigen Rapid Test SERO (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection MESHD

    Authors: Hendrik Gremmels; Beatrice M.F. Winkel; Rob Schuurman; Andert Rosingh; Nicolette A.M. Rigter; Olga Rodriguez; Johan Ubijaan; Annemarie M.J. Wensing; Marc J.M. Bonten; Laura Marije Hofstra; Ana M Dias; Ivan-Christian Kurolt; Alemka Markotic; Dragan Primorac; Adriana Soares; Luis Malheiro; Irena Trbojevic-Akmacic; Miguel Abreu; Rui Sarmento e Castro; Silvia Bettinelli; Annapaola Callegaro; Marco Arosio; Lorena Sangiorgio; Luca Lorini; Xavier Castells; Juan P Horcajada; Salome Pinho; Massimo Allegri; Clara Barrios; Gordan Lauc

    doi:10.1101/2020.10.16.20214189 Date: 2020-10-20 Source: medRxiv

    Background: RT-qPCR is the reference test for identification of active SARS-CoV-2 infection MESHD, but is associated with diagnostic delay. Antigen detection assays can generate results within 20 minutes and outside of laboratory settings. Yet, their diagnostic test performance SERO in real life settings has not been determined. Methods: The diagnostic value of the Panbio COVID-19 Ag Rapid Test SERO (Abbott), was determined in comparison to RT-qPCR (Seegene Allplex) in community-dwelling mildly symptomatic subjects in a medium (Utrecht, the Netherlands) and high endemic area (Aruba), using two concurrently obtained nasopharyngeal swabs. Findings: 1367 and 208 subjects were enrolled in Utrecht and Aruba, respectively. SARS-CoV-2 prevalence SERO, based on RT-qPCR, was 10.2% (n=139) and 30.3% (n=63) in Utrecht and Aruba respectively. Specificity of the Panbio COVID-19 Ag Rapid Test SERO was 100% (95%CI: 99.7-100%) in both settings. Test sensitivity SERO was 72.6% (95%CI: 64.5-79.9%) in the Netherlands and 81.0% (95% CI: 69.0-89.8%) in Aruba. Probability of false negative results was associated with RT-qPCR Ct-values, but not with duration of symptoms. Restricting RT-qPCR test positivity to Ct-values <32 yielded test sensitivities SERO of 95.2% (95%CI: 89.3-98.5%) in the Netherlands and 98.0% (95%CI: 89.2-99.95%) in Aruba. Interpretation: In community-dwelling subjects with mild respiratory symptoms the Panbio COVID-19 Ag Rapid Test SERO had 100% specificity, and a sensitivity SERO above 95% for nasopharyngeal samples when using Ct values <32 cycles as cut-off for RT-qPCR test positivity. Considering short turnaround times, user friendliness, low costs and opportunities for decentralized testing, this test can improve our efforts to control transmission TRANS of SARS-CoV-2. Funding: UMCU and LABHOH, Aruba

    The relationship between cardiac injury MESHD, inflammation and coagulation MESHD in predicting COVID-19 outcome

    Authors: Alessandro Mengozzi; Georgios Georgiopoulos; Marco Falcone; Giusy Tiseo; Nicola Riccardo Pugliese; Meletios A Dimopoulos; Lorenzo Ghiadoni; Greta Barbieri; Francesco Forfori; Laura Carrozzi; Massimo Santini; Fabio Monzani; Salvatore De Marco; Francesco Menichetti; Agostino Virdis; Stefano Masi

    doi:10.21203/ Date: 2020-10-18 Source: ResearchSquare

    Introduction: High sensitivity SERO troponin T (hsTnT) is a strong predictor of adverse outcome during SARS-CoV-2 infection MESHD. However, its determinants remain partially unknown. We aimed to assess the relationship between severity of inflammatory response/ coagulation abnormalities HP coagulation abnormalities MESHD and hsTnT in Coronavirus Disease MESHD 2019 (COVID-19). We then explored the relevance of these pathways in defining mortality and complications risk and the potential effects of the treatments to attenuate such risk.Methods: In this single-center, prospective, observational study we enrolled 266 consecutive patients hospitalized for SARS-CoV-2 pneumonia MESHD pneumonia HP. Primary endpoint was in-hospital COVID-19 mortality. Results: hsTnT, even after adjustment for confounders, was associated with mortality. D-dimer and CRP presented stronger associations with hsTnT than PaO2. Changes of hsTnT, D-dimer and CRP were related but only D-dimer was associated with mortality. Moreover, low molecular weight heparin showed attenuation of the mortality in the whole population, particularly in subjects with higher hsTnT.Conclusions: D-dimer possessed a strong relationship with hsTnT and mortality. Anticoagulation treatment showed greater benefits with regard to mortality. These findings suggest a major role of SARS-CoV-2 coagulopathy MESHD in hsTnT elevation and its related mortality in COVID-19. A better understanding of the mechanisms related to COVID-19 might pave the way to therapy tailoring in these high-risk individuals.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.